Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

NCT07496567 is registered in ClinicalTrials.gov with EyeBiotech Ltd. as lead sponsor.

NCT NCT07496567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07496567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Lead sponsor
EyeBiotech Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 15, 2026
Completion date
July 31, 2028
Enrollment
960 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, choroidal neovascularization, macular degeneration, wet macular degeneration